SAGE Therapeutics (SAGE) Receives a Buy from William Blair
In a report issued on September 11, Tim Lugo from William Blair maintained a Buy rating on SAGE Therapeutics (SAGE). The company’s shares closed last Wednesday at $61.12.
According to TipRanks.com, Lugo is a 5-star analyst with an average return of 14.5% and a 48.2% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, BioMarin Pharmaceutical, and Adamas Pharmaceuticals.
SAGE Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $69.82, representing a 17.9% upside. In a report issued on September 10, RBC Capital also maintained a Buy rating on the stock with a $75.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $155.33 and a one-year low of $25.01. Currently, SAGE Therapeutics has an average volume of 683.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.